The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2016 | Perspectives on future paths to cure multiple myeloma
Antonio Palumbo, MD, from the University of Turin, Turin, Italy, provides an overview of his talk on ‘Perspectives on future paths to cure’ held at the Myeloma 2016 meeting in Boston, MA. According to Dr Palumobo, the key message is that the survival of patients with multiple myeloma (MM) has improved over the last 15 years. Dr Palumbo further discusses the prospect of being able to cure a proportion of patients and further highlights that currently, the use of a dose intense treatment at diagnosis is important as with this approach, remission durations of around six or even ten years are achievable.
